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Abstract
Background: Subjective cognitive decline (SCD) is a potential risk factor for dementia. We aimed to investigate the
association between SCD and subsequent dementia in a nationwide population-based cohort in South Korea.
Methods: This cohort included 579,710 66-year-old adults who were followed for a total of 3,870,293 person-years
(average 6.68 ± 1.33 years per person). All subjects completed a questionnaire about subjective memory impairment,
the Pre-screening Korean Dementia Screening Questionnaire (KDSQ-P), which included a validated 5-item derivative,
and were determined to have SCD based on a single question assessing memory decline. Depressive symptoms
were assessed in all subjects using a 3-item modified geriatric depression scale. Hazard ratios were estimated using
the Cox proportional hazards model and compared between subjects with and without SCD.
Results: Compared to subjects without SCD, those with SCD were more likely to develop dementia (incidence per
1000 person-years: non-SCD, 5.66; SCD, 8.59). After adjusting for potential confounding factors, the risk of
subsequent dementia significantly increased in subjects with SCD, with an adjusted hazard ratio (aHR) of 1.38 (95%
confidence interval [CI] 1.34 to 1.41). The risk of subsequent dementia was greatly increased in subjects with higher
KDSQ-P scores (aHR = 2.77, 95% CI 2.35 to 3.27). A significant association between SCD and dementia was observed
in both depressive and non-depressive symptom groups (aHR = 1.50, 95% CI 1.42 to 1.57 in subjects with
depressive symptoms; aHR = 1.33, 95% CI 1.29 to 1.37 in subjects without depressive symptoms; P = 0.001).
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Conclusions: In this population of 66-year-old individuals, SCD was significantly associated with an increased risk of
subsequent dementia. This association was found in both depressive and non-depressive groups, with an increased
risk of dementia in the presence of depressive symptoms. Our findings suggest that SCD indicates a risk for
dementia. Further studies are needed to delineate potential approaches to preventing the development of
dementia in individuals with SCD.
Keywords: Subjective cognitive decline, Subjective memory impairment, Alzheimer’s disease, Dementia, Depression,
Preclinical Alzheimer’s disease
Background
Dementia represents one of the most prevalent neurode-
generative disorders worldwide and is present in ap-
proximately 10% of people aged 65 years and older [1].
Moreover, the public health burden of dementia is grow-
ing more rapidly than any other disease [2]. It has been
reported that almost 80% of people worry about devel-
oping dementia [3] and identify dementia as their most
feared illness, over cancer, heart disease, stroke, and dia-
betes [4]. Aging is concomitant with increased episodes
of forgetfulness, and memory complaints are prevalent
in approximately 25 to 50% of older adults [5]. Previous
studies have found that memory complaints may relate
to subclinical psychiatric symptoms [5–7], but they can
also represent an early indicator of dementia, including
Alzheimer’s disease (AD) [8–12]. Considering the grow-
ing number of patients with dementia and the associated
medical and societal burden, it is important to
characterize at-risk groups or preclinical states of de-
mentia in order to facilitate early interventions to reduce
cognitive impairment in the future.
As part of this effort, considerable progress has been
made investigating the prospective dementia risk associ-
ated with subjective cognitive decline (SCD) [13, 14].
SCD refers to a subjective experience of cognitive de-
cline without objective cognitive deficits [14]. Research
indicates that SCD may represent an early symptom of
AD signifying the preclinical stage [9–12], which can
progress to mild cognitive impairment (MCI) and de-
mentia in the AD continuum [12–15]. However, SCD is
also associated with poor physical health and with psy-
chiatric disorders such as depression, which confounds
the association with dementia [16, 17]. For example, de-
pression is a major risk factor for dementia, and previous
work has indicated that SCD could be linked with sub-
syndromal depressive symptoms rather than with subse-
quent dementia [18]. The considerable heterogeneity
present across numerous small studies has contributed
to conflicting results and has prevented consensus in the
field [16–18].
Regarding the recruitment setting, it has been ob-
served that SCD in memory clinic cases increased the
risk of dementia [10], whereas SCD in community
populations showed less significant or non-significant as-
sociations [10, 19]. Given that the concerns and health-
seeking behaviors of community-recruited older adults
may differ from those of memory clinic patients [10], in-
vestigations using a large community sample would im-
prove the accuracy for estimating the SCD-associated
risk for incident dementia in the general population.
This study analyzed a nationwide population-based co-
hort that includes 51.8% of the 66-year-old adult popula-
tion in South Korea. We aimed (1) to determine
whether the risk of subsequent dementia increases in
subjects with SCD compared to those without SCD, (2)
to evaluate whether the severity of subjective memory
impairment is associated with subsequent dementia, and
(3) to examine whether depressive symptoms affect the
association between SCD and subsequent dementia.
Methods
Data sources and study cohort
Data were obtained from the South Korean National
Health Insurance Service (NHIS) database (supplemen-
tary methods) [20]. The NHIS provides mandatory
healthcare for 97% of South Koreans under a single-
payer model. Further, it provides the National Screening
Program for Transitional Ages (NSPTA), an age-specific
national health examination program for all Korean citi-
zens aged 40 and 66 [21]. Our study population con-
sisted of a subset of individuals from the NHIS database
who participated in the NSPTA at age 66, between 2009
and 2011. The study population covered 51.8% of the
total South Korean population aged 66 during the enrol-
ment period. This study was approved by the Institu-
tional Review Board of Seoul National University
Bundang Hospital. Because the NHIS provided
encrypted data to protect private information, the need
to obtain informed consent was waived (approval No. X-
1901-517-902).
Inclusion and exclusion criteria
We included all subjects who had available information
on the Pre-screening Korean Dementia Screening Ques-
tionnaire (KDSQ-P), a cognitive function questionnaire
[22]. The exclusion criteria were as follows: (1)
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individuals who reported impaired function in activities
of daily living (ADLs) because of possible pre-existing
dementia (ADLs were assessed by a questionnaire con-
sisting of six questions derived from a modified Korean
Activities of Daily Living Scale and Korean Instrumental
Activities of Daily Living Scale [23]); (2) individuals with
dementia (ICD-10 [International Classification of Dis-
ease, 10th revision] code F00-F03, G30, or G31), mild
cognitive impairment (ICD-10 code F06·7), or docu-
mented history of dementia medication (donepezil, riv-
astigmine, galantamine, or memantine) before the index
date; (3) individuals with a psychotic disorder (ICD-10
code F20-F29; these criteria were applied to approxi-
mately meet the research criteria for pre-mild cognitive
impairment SCD suggested in a previous study [14]); (4)
individuals with missing or duplicate data on the pri-
mary variable of interest or covariates; (5) individuals
with outlier values in continuous variables (mean ± 4
standard deviations); and (6) individuals who died or
dropped out between the time they participated in the
NSPTA and the index date. From the 650,861 subjects
who took the NSPTA, 71,150 subjects (10.9%) were ex-
cluded according to the exclusion criteria (see Figure S1
in the online supplement).
Primary independent variable of interest: SCD
SCD was defined as an answer of “yes” to item 2 of the
KDSQ-P. KDSQ-P is a validated questionnaire that con-
sists of five questions [22]. Each item can be self-
answered with three possible choices: “no,” “sometimes
yes,” or “frequently yes,” scored as 0, 1, and 2, respect-
ively. Overall KDSQ-P scores range from 0 to 10, with
higher scores indicating greater degrees of subjective
memory impairment. Those who score ≥ 4 points are ad-
vised to seek further evaluation of their cognitive func-
tion. All items of the KDSQ-P are presented in Table S1
in the online supplement. We defined SCD based on
scoring a 1 or 2 (a positive answer) on the responses to
item 2, which asks about the subjective decline in the
memory domain and was suggested in the conceptual
framework for research on SCD: “Do you think your
memory has declined compared to a year ago?” [14].
Subjective memory impairment and depressive
symptoms
The severity of the subjective memory impairment was
defined using the total score on the KDSQ-P ranging
from 0 to 10 [22]. The presence of depressive symptoms
was defined as a Depression Screening Questionnaire
(DSQ) score > 0. This questionnaire includes three ques-
tions derived from a modified geriatric depression scale
[24] (e.g., “Have you lost much of your activity or motiv-
ation these days?,” “Do you feel that you are worthless
now?,” and “Do you feel that you have no hope now?”).
Each question can be self-answered with two possible
choices, “yes” or “no,” scored as 1 or 0, respectively.
Total DSQ scores range from 0 to 3, with higher scores
indicating more depressive symptoms.
Primary outcomes
The primary outcome was the incidence of dementia fol-
lowing SCD. Dementia was defined based on the Inter-
national Statistical Classification of Diseases, 10th
revision codes (F00-F03, G30, or G31; Table S2) and the
use of cognitive-enhancing medications based on previ-
ous studies [25, 26]. This definition is relevant to our
study considering that the Korean government covers
medical expenditure for dementia based on ICD-10
codes. Additionally, clinicians are required to document
ICD-10 codes for dementia as well as the results of
neuropsychological tests to prescribe cognitive-
enhancing medications. The date of onset of dementia
was considered the first date for which patients were
both diagnosed with dementia and prescribed with de-
mentia medication.
Covariates
We assessed demographic variables such as sex and in-
come. Lifestyle variables such as smoking status, alcohol
consumption habits, and exercise frequency were in-
cluded as covariates. We further adjusted for healthcare
visit frequency, laboratory test results, physical examin-
ation results, and the patient’s medical history, including
information related to psychiatric disorders, neurological
diseases, and other medical diseases (Table S2). To as-
sess depressive symptoms, we used the DSQ score. De-
tailed information is presented in the supplementary
methods.
Statistical analysis
To investigate the association between SCD and the in-
cidence of dementia, study participants were followed
from the index date (1 January of the year after each
participant participated in the NSPTA) to the date of
onset of dementia, death, or the end of follow-up (31
December 2017), whichever occurred first. For all partic-
ipants, between-group differences for continuous vari-
ables and categorical variables were assessed using t
tests and chi-squared tests, respectively. A Cox propor-
tional hazard regression analysis was conducted to deter-
mine adjusted hazard ratios (aHRs) for SCD in
predicting subsequent dementia, after controlling for co-
variates. The effect of SCD on subsequent dementia was
first analyzed in an unadjusted model and then in a sex-
adjusted and three additional models adjusted for vari-
ous covariates (models 1 to 3). In the secondary analysis,
we used the total KDSQ-P score as an independent vari-
able to evaluate the association between the severity of
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subjective memory impairment and subsequent demen-
tia. We also calculated aHR separately for score 1 and
score 2 for each item of the KDSQ-P and the aHR of
score 2 compared to score 1 only in the SCD group. We
used an SCD and depressive symptom (coded as dichot-
omous variables: 0 indicating the absence of any depres-
sive symptoms and 1 indicating the presence of any
depressive symptoms among the three DSQ items) inter-
action term to test the potential for an interaction effect
on subsequent dementia.
The proportional hazards assumption was graphically
tested and verified using the Schoenfeld residual
method. No variables violated the proportional hazards
assumption. Multicollinearity between all covariates was
tested using a variance inflation factor (VIF), and no sig-
nificant collinearity was found (VIF < 4 for all variables).
After conducting a survival analysis of all participants,
we performed an additional analysis by sampling the
control group using the propensity score matching
method based on logistic regression [27] using the
Matchit packages in R (http://cran.r-project.org). We
also performed several sensitivity analyses to confirm the
robustness of the main findings. Firstly, we excluded pa-
tients who developed dementia within a year of the
index date because those patients may not be incident
cases. Secondly, we conducted separate analyses by de-
mentia subtypes (AD and non-AD cases) to examine
whether the association between SCD and dementia dif-
fers by dementia subtypes. Thirdly, we excluded patients
with a history of psychiatric disorders, patients with a
history of neurological diseases, or patients with depres-
sive symptoms according to the DSQ (DSQ > 0), because
the presence of these disorders/diseases may confound
the association of SCD with dementia affecting the de-
mentia risk. Finally, we excluded patients with a KDSQ-
P score ≥ 4 (the cutoff point for further dementia screen-
ing tests [22]) to more rigorously exclude preexisting de-
mentia cases.
Statistical analyses were conducted using two-tailed
tests, a significance level of 0.05, and 95% confidence in-
tervals (CIs). All analyses were conducted using SAS En-
terprise Guide version 7.2 (SAS Institute, Inc.) and R
Studio version 1.0.136 (RStudio, Inc., with packages Sur-
vival version 2.43-3 and Survminer version 0.4.3).
Results
During the period from 2009 to 2011, a total of 650,861
individuals participated in the NSPTA and had KDSQ-P
information available. Of these, we excluded 21,458 indi-
viduals who reported impaired ADL function; 12,658 in-
dividuals with dementia, MCI, or with a documented
history of cognitive-enhancing medication; 18,760 indi-
viduals with missing or duplicate data; 14,315 individuals
with outlier data; 2632 individuals with a psychotic
disorder; and 1328 individuals who died or were lost to
follow-up between their NSPTA participation date and
the index date. In total, 579,710 subjects were included
in the final study population for analysis, of which 222,
056 (38.3%) experienced SCD (see the flowchart of study
participants in Figure S1 in the online supplement).
They were followed for an average of 6.68 ± 1.33 years
per person and a total of 3,870,293 person-years.
Subject characteristics
The clinical and demographic characteristics of the par-
ticipants at baseline are presented in Table 1. The study
population consisted of 266,311 (45.9%) men and 313,
399 (54.1%) women. Compared to individuals in the
non-SCD group, those with SCD tended to be women,
did not smoke, consumed more alcohol, exercised more,
visited healthcare facilities more frequently, had more
medical or medication history, had higher cholesterol
levels, and had lower fasting glucose, hemoglobin, and
blood pressure.
Risk of subsequent dementia according to SCD
Among individuals with SCD, the incidence of dementia
was 8.59 per 1000 person-years, which was higher than
individuals without SCD who developed dementia at an
incidence of 5.66 per 1000 person-years (Table 2). The
SCD group had a higher cumulative incidence of demen-
tia compared to the non-SCD group (log-rank P < 0.001,
Fig. 1). When adjusted for clinical factors (model 3),
subjects with SCD had an increased risk of subsequent
dementia (aHR = 1.38, 95% CI 1.34 to 1.41 in model 3;
see Table 2). The aHRs were consistent in both men and
women across all Cox regression models tested, despite
controlling for various covariates. The effect of inter-
action between SCD and sex on subsequent dementia
was not significant (Table S3 in the online supplement).
The propensity score-matched analysis also confirmed
that the presence of SCD increased the risk of subse-
quent dementia (aHR = 1.39, 95% CI 1.36 to 1.43 in
model 3). The incidence of AD and dementia other than
AD during the follow-up period is presented in Table S2
in the online supplement. The incidence rates of demen-
tia associated with other risk factors including smoking,
alcohol consumption, exercise frequency, depression,
cerebrovascular disease, and diabetes mellitus are pre-
sented in Table S4 in the online supplement.
Association between severity of subjective memory
impairment and subsequent dementia
The severity of subjective memory impairment, total
KDSQ-P score, was significantly associated with risk of
subsequent dementia (Fig. 2). Subjects with a higher
KDSQ-P score showed a strong tendency for a higher
risk for subsequent dementia. The risk of dementia in
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Table 1 Descriptive characteristics of the study population
Total (n = 579,710) Non-SCD group (n = 357,654) SCD group (n = 222,056) P value
Sex < 0.0001
Male 266,311 (45.9%) 173,795 (48.6%) 92,516 (41.7%)
Female 313,399 (54.1%) 183,859 (51.4%) 129,540 (58.3%)
Income < 0.0001
Medicaid aid 33,023 (5.7%) 19,101 (5.3%) 13,922 (6.3%)
Group 1 (1st to 6th ventiles) 125,064 (21.6%) 82,491 (23.1%) 42,573 (19.2%)
Group 2 (7th to 14th ventiles) 178,625 (30.8%) 110,550 (30.9%) 68,075 (30.7%)
Group 3 (15th to 20th ventiles) 242,998 (41.9%) 145,512 (40.7%) 97,486 (43.9%)
Lifestyle factors
Smoking status < 0.0001
Never smoked 406,103 (70.1%) 250,238 (70.0%) 155,865 (70.2%)
Ex-smoker 95,502 (16.5%) 57,647 (16.1%) 37,855 (17.0%)
Current smoker 78,105 (13.5%) 49,769 (13.9%) 28,336 (12.8%)
Alcohol consumption < 0.0001
No drinking: rarely 508,547 (87.7%) 314,324 (87.9%) 194,223 (87.5%)
Light drinking: 3–4 times per week 38,840 (6.7%) 23,954 (6.7%) 14,886 (6.7%)
Heavy drinking: almost every day 32,323 (5.6%) 19,376 (5.4%) 12,947 (5.8%)
Exercise frequency < 0.0001
Exercise 327,775 (56.5%) 200,723 (56.1%) 127,052 (57.2%)
No exercise 251,935 (43.5%) 156,931 (43.9%) 95,004 (42.8%)
Healthcare visit frequency*
First quartile 144,858 (25.0%) 93,542 (26.2%) 51,316 (23.1%)
Second quartile 144,945 (25.0%) 89,583 (25.1%) 55,362 (24.9%)
Third quartile 144,988 (25.0%) 88,208 (24.7%) 56,780 (25.6%)
Fourth quartile 144,919 (25.0%) 86,321 (24.1%) 58,598 (26.4%)
Past medical history
Psychiatric disorders
Depression 48,653 (8.4%) 26,676 (7.5%) 21,977 (9.9%) < 0.0001
Bipolar affective disorder 1891 (0.3%) 1059 (0.3%) 832 (0.4%) < 0.0001
Substance use disorder 3522 (0.6%) 2035 (0.6%) 1487 (0.7%) < 0.0001
Panic disorder 2315 (0.4%) 1298 (0.4%) 1017 (0.5%) < 0.0001
Obsessive-compulsive disorder 671 (0.1%) 370 (0.1%) 301 (0.1%) 0.001
Personality disorder 237 (0.0%) 142 (0.0%) 95 (0.0%) 0.619
Other psychiatric disorders 140,212 (24.2%) 81,764 (22.9%) 58,448 (26.3%) < 0.0001
Neurological diseases
Cerebrovascular disease 80,212 (13.8%) 46,895 (13.1%) 33,317 (15.0%) < 0.0001
Epilepsy 8622 (1.5%) 4807 (1.3%) 3815 (1.7%) < 0.0001
Migraines 43,466 (7.5%) 25,304 (7.1%) 18,162 (8.2%) < 0.0001
Headaches 70,207 (12.1%) 40,791 (11.4%) 29,416 (13.2%) < 0.0001
Sleep disorder 63,769 (11.0%) 36,635 (10.2%) 27,134 (12.2%) < 0.0001
Head injury 64,698 (11.2%) 39,459 (11.0%) 25,239 (11.4%) < 0.0001
Medical diseases
Diabetes mellitus 154,977 (26.7%) 94,346 (26.4%) 60,631 (27.3%) < 0.0001
Myocardial infarction 8504 (1.5%) 5245 (1.5%) 3259 (1.5%) 0.981
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subjects with a score of 9 or 10 was approximately three
times higher than in subjects with a score of 0. Each
item in the KDSQ-P was also significantly associated
with the risk of subsequent dementia (see Table S1 in
the online supplement). Subjects who answered “fre-
quently yes” for each question had a higher risk for sub-
sequent dementia than those who answered “sometimes
yes.”
Effect of interaction between SCD and depressive
symptoms on subsequent dementia
Figure 3 shows the estimated effect of SCD on subse-
quent dementia after accounting for depressive symp-
toms. Regardless of the presence of depressive
symptoms, SCD was significantly associated with a risk
for subsequent dementia. Notably, the effect of SCD on
subsequent dementia was particularly prominent in the
presence of depressive symptoms (in subjects with de-
pressive symptoms, aHR = 1.50, 95% CI 1.42 to 1.57; in
subjects without depressive symptoms, aHR = 1.33, 95%
CI 1.29 to 1.37; interaction P = 0.001).
Sensitivity analysis for the association between SCD and
subsequent dementia
Even after iteratively removing subgroups from our sub-
jects, the risk of subsequent dementia was consistently
associated with SCD (see Table S5 in the online supple-
ment). First, we excluded patients diagnosed with subse-
quent dementia within 1 year of the index date to avoid
the onset of actual dementia before reporting SCD. By
excluding these patients, our analysis demonstrated the
robustness of the link between SCD and subsequent de-
mentia in our study cohort (aHR = 1.37, 95% CI 1.34 to
1.41 in model 3). The results were also consistent when
subsequent dementia was subdivided into AD (only in-
cluding AD, aHR = 1.38, 95% CI 1.35 to 1.42 in model 3)
and dementia other than AD (only including dementia
other than AD, aHR = 1.37, 95% CI 1.30 to 1.45 in model
Table 1 Descriptive characteristics of the study population (Continued)
Total (n = 579,710) Non-SCD group (n = 357,654) SCD group (n = 222,056) P value
Congestive heart failure 31,952 (5.5%) 19,222 (5.4%) 12,730 (5.7%) < 0.0001
Liver disease 146,020 (25.2%) 88,392 (24.7%) 57,628 (26.0%) < 0.0001
Renal disease 5669 (1.0%) 3476 (1.0%) 2193 (1.0%) 0.564
Peptic ulcer disease 259,797 (44.8%) 155,929 (43.6%) 103,868 (46.8%) < 0.0001
Thyroid gland disorder 40,236 (6.9%) 23,104 (6.5%) 17,132 (7.7%) < 0.0001
Asthma 123,850 (21.4%) 74,598 (20.9%) 49,252 (22.2%) < 0.0001
Cancer 41,290 (7.1%) 24,845 (6.9%) 16,445 (7.4%) < 0.0001
Medication history
HMG-CoA reductase inhibitors 128,527 (22.2%) 77,725 (21.7%) 50,802 (22.9%) < 0.0001
Diabetes medication 84,015 (14.5%) 51,878 (14.5%) 32,137 (14.5%) 0.735
Antihypertensive medication 288,262 (49.7%) 178,093 (49.8%) 110,169 (49.6%) 0.180
Antidepressants 31,079 (5.4%) 17,216 (4.8%) 13,863 (6.2%) < 0.0001
Benzodiazepines and sleeping pills 92,444 (15.9%) 53,108 (14.8%) 39,336 (17.7%) < 0.0001
Antiplatelet medication 140,615 (24.3%) 86,071 (24.1%) 54,544 (24.6%) < 0.0001
Depression Screening Questionnaire score, mean (SD) 0.34 (0.79) 0.23 (0.67) 0.53 (0.92) < 0.0001
Laboratory findings
Cholesterol level, mean (SD), mg/dL
LDL cholesterol 117.47 (35.58) 117.26 (35.55) 117.81 (35.64) < 0.0001
HDL cholesterol 53.63 (13.64) 53.57 (13.61) 53.73 (13.68) < 0.0001
Triglycerides 134.31 (70.64) 134.80 (70.97) 133.54 (70.10) < 0.0001
Fasting glucose 101.89 (20.96) 102.11 (21.10) 101.52 (20.73) < 0.0001
Hemoglobin 13.59 (1.40) 13.63 (1.40) 13.54 (1.39) < 0.0001
Physical examination findings
Body mass index 24.29 (2.98) 24.31 (2.99) 24.25 (2.98) < 0.0001
Systolic blood pressure 128.74 (15.43) 129.05 (15.44) 128.22 (15.41) < 0.0001
Diastolic blood pressure 78.01 (9.73) 78.18 (9.73) 77.73 (9.73) < 0.0001
HDL high-density lipoprotein, LDL low-density lipoprotein, SCD subjective cognitive decline, SD standard deviation
*The fourth quartile group had the highest frequency of medical visits
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3). The definition and the incidence of dementia other
than AD are presented in Table S2. We also observed a
significant link after excluding individuals with psychi-
atric disorders (aHR = 1.38, 95% CI 1.34 to 1.43 in model
3), patients with neurological diseases (aHR = 1.43, 95%
CI 1.38 to 1.49 in model 3), patients with depressive
symptoms according to the DSQ (aHR = 1.33, 95% CI
1.29 to 1.37 in model 3), and patients with KDSQ-P
scores ≥ 4 (aHR = 1.18, 95% CI 1.14 to 1.21 in model 3).
In addition, the association between the severity of SCD
(score 1 or 2 to item 2) and the risk of dementia
remained significant after excluding the non-SCD group
(score 0 to item 2) (Table S6 in the online supplement).
Discussion
In this nationwide population-based study of 579,710
66-year-old adults, subjects with SCD were more likely
to develop subsequent dementia than those without
SCD over an average follow-up period of 6.68 years. The
association between SCD and subsequent dementia was
robust across sex, subtype of dementia (AD or other
than AD), history of psychiatric disorders or neuro-
logical diseases, and presence of depressive symptoms.
The severity of subjective memory impairment was also
associated with the risk of subsequent dementia. Fur-
thermore, regardless of the presence of depressive symp-
toms, SCD was significantly associated with subsequent
dementia, with an increased association in the presence
of depressive symptoms.
The positive association between SCD and subsequent
dementia found in our study is generally consistent with
previous studies. A recent population-based study (n =
2710) reported an aHR in SCD similar to that of our
study (aHR = 1.18, 95% CI 1.03 to 1.33) [19]. The
Table 2 Cox regression analysis for the association between subjective cognitive decline and subsequent dementia
Non-SCD group SCD group
Total population 357,654 (61.7%) 222,056 (38.3%)
Dementia events 13,501 (3.8%) 12,766 (5.8%)
Person-years 2,384,745 1,485,548
Incidence (events/1000 person-years) 5.66 8.59
Unadjusted HR (95% CI) 1 [reference] 1.51 (1.47–1.55)
Sex-adjusted HR (95% CI) 1 [reference] 1.48 (1.44–1.51)
aHR in model 1 (95% CI)* 1 [reference] 1.46 (1.43–1.50)
aHR in model 2 (95% CI)† 1 [reference] 1.42 (1.39–1.46)
aHR in model 3 (95% CI)‡ 1 [reference] 1.38 (1.34–1.41)
Men 173,795 (48.6%) 92,516 (41.7%)
Dementia events 5480 (3.2%) 4399 (4.8%)
Person-years 1,147,608 611,069.20
Incidence (events/1000 person-years) 4.78 7.20
Unadjusted HR (95% CI) 1 [reference] 1.50 (1.44–1.56)
aHR in model 1 (95% CI)* 1 [reference] 1.49 (1.43–1.55)
aHR in model 2 (95% CI)† 1 [reference] 1.44 (1.39–1.50)
aHR in model 3 (95% CI)‡ 1 [reference] 1.38 (1.32–1.44)
Women 183,859 (51.4%) 129,540 (58.3%)
Dementia events 8021 (4.4%) 8367 (6.5%)
Person-years 1,237,137 874,478.80
Incidence (events/1000 person-years) 6.48 9.57
Unadjusted HR (95% CI) 1 [reference] 1.47 (1.42–1.51)
aHR in model 1 (95% CI)* 1 [reference] 1.45 (1.40–1.49)
aHR in model 2 (95% CI)† 1 [reference] 1.41 (1.37–1.45)
aHR in model 3 (95% CI)‡ 1 [reference] 1.38 (1.33–1.42)
aHR adjusted hazard ratio, CI confidence interval, SCD subjective cognitive decline
*Adjusted for sex, income, lifestyle factors, and healthcare visit frequency (in subgroup analysis for men and women, sex was not entered as a covariate)
†Adjusted for sex, income, lifestyle factors, healthcare visit frequency, medical history, and medication history (in subgroup analysis for men and women, sex was
not entered as a covariate)
‡Adjusted for sex, income, lifestyle factors, healthcare visit frequency, medical history, medication history, depression screening questionnaire scores, laboratory
findings, and physical examination findings (in subgroup analysis for men and women, sex was not entered as a covariate)
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prevalence of SCD in our study was 38.3% (222,056 in
579,710), which is comparable to the prevalence estimates
of previous community-based studies, which ranged from
22.1 to 56.0% [5]. However, the rate of incident dementia
and risk of subsequent dementia in the SCD group com-
pared to the non-SCD group in our study was lower than
in previous research. In a recent multicenter cohort study
of 4369 participants, the incidence rate of dementia in
SCD cases was reported to be 17.7 per 1000 person-years
[10], which is higher than our result of 8.6 per 1000
person-years. Discrepancies between our results and those
of previous SCD studies may be due to the heterogeneity
of the study populations [10, 12]. Reports have indicated
that, when compared to community populations, patients
who visited memory clinics had a higher progression rate
from normal cognition to MCI [28], from SCD to AD
[10], and from MCI to AD [29].
The higher progression rate observed in memory clinic
samples has been attributed to the subjects’ greater like-
lihood of experiencing the early signs of
neurodegenerative diseases and of spontaneously report-
ing memory complaints [9, 10, 14, 28, 29]. More import-
antly, decreased functional abilities were found in
memory clinic attendees at baseline, which significantly
indicates a risk for dementia [28, 29]. In contrast to pre-
vious studies, our study consisted of subjects obtained
from a population-based setting, and thus better illus-
trates the robust association between SCD and subse-
quent dementia in the general population. In accordance
with a previous study [19], our analyses revealed equiva-
lent incidence rates of dementia associated with SCD
(8.6 per 1000 person-years) and other risk factors in-
cluding current smoking (7.24/1000 person-years), heavy
alcohol drinking (7.44/1000 person-years), no exercise
(7.54/1000 person-years), diabetes mellitus (8.91/1000
person-years), cerebrovascular disease (11.34/1000
person-years), and depression (12.46/1000 person-years).
This result suggests that SCD has a similar magnitude of
risk for subsequent dementia as other lifestyle and vas-
cular risk factors in a community population.
Fig. 1 Kaplan-Meier estimates of the incidence of dementia. Cumulative incidence of dementia in non-SCD and SCD groups. SCD, subjective
cognitive decline. *A significantly increased risk of dementia was found in the SCD group
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Our analysis showed a higher incidence of dementia in
women with SCD than in men with SCD (9.57 vs. 7.20/
1000 person-years), but the risk of dementia associated
with SCD was comparable in both sexes after adjusting
for various factors (aHR = 1.38, 95% CI 1.33 to 1.42 for
women; aHR = 1.38, 95% CI 1.32 to 1.44 for men; Table 2
and Table S3 in the online supplement). Some studies
reported women to be more susceptible than men to
Fig. 2 Adjusted HRs for dementia according to the Pre-screening Korean Dementia Screening Questionnaire (KDSQ-P) score. Blue dots indicate
the adjusted HR, and blue lines indicate the 95% confidence intervals. HR, hazard ratio; CI, confidence interval; KDSQ-P, Pre-screening Korean
Dementia Screening Questionnaire. aAdjusted for sex, income, lifestyle factors, healthcare visit frequency, past medical history, medication history,
Depression Screening Questionnaire score, laboratory findings, and physical examination findings
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progression from SCD to dementia [30, 31], whereas
others found no significant sex difference [8, 10, 19].
Some have reported a tendency for women to report
SCD worries with a higher sensitivity to subtle cognitive
symptoms relating to dementia progression when com-
pared to men [32]. Women are also known to be suscep-
tible to dementia, possibly due to their longevity and
sex-specific biological factors [33]. However, in our
study with the largest sample size, before and after
adjusting for various clinical factors and sociodemo-
graphic variables, the risk of dementia associated with
SCD was comparable in both sexes.
Our results also highlight the positive linear association
between the severity of subjective memory impairment
and subsequent dementia (Fig. 2). This finding suggests
that the more severe the subjective memory complaints,
the greater the risk of subsequent dementia. KDSQ-P, a
validated pre-screening tool for dementia [22], includes
items measuring subjective memory using multiple re-
sponse types. In recent studies, many authors have
evaluated SCD with multiple items [34, 35], and some
have administered face-to-face interviews [8, 30, 34, 36].
Moreover, many of them asked about specific memory
(70.7%) and functional decline (41.6%) to assess SCD [34].
The single question defining SCD in this study lacked in-
formation on concerns, non-memory domains, and im-
pairment. However, the use of a general question to
identify the presence of SCD and a variety of additional
questions regarding specific subjective memory impair-
ment may also clarify the effect of well-defined features of
SCD on subsequent dementia.
In this study, the SCD group with depressive symp-
toms had a greater risk for subsequent dementia than
the group without depressive symptoms, with a signifi-
cant interaction effect (Fig. 3). Although depressive
symptoms are regarded as a crucial factor for subsequent
dementia due to their association with cognitive disor-
ders [7, 13, 16, 37], previous studies have found a min-
imal effect of mood scores on the association between
SCD and further cognitive decline [8, 19, 38]. This is
Fig. 3 The interaction effect between SCD and depressive symptoms on subsequent dementia. Cumulative incidence of dementia in groups
according to the presence of SCD and depressive symptoms. ‡A significant interaction was found between SCD and depressive symptoms. SCD,
subjective cognitive decline; HR, hazard ratio; CI, confidence interval. aAdjusted for sex, income, lifestyle factors, healthcare visit frequency, past
medical history, medication history, laboratory findings, and physical examination findings
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possibly attributable to the limited size of the studies.
Our results imply that SCD and depressive symptoms
not only act independently as risk factors for dementia
but also contribute to its development through their
interaction.
We observed that SCD was likely to be an incipient
symptom of both AD and non-AD-related dementias (see
Table S5 in the online supplement). Studies have suggested
that SCD is related to AD pathology. It has been demon-
strated that AD biomarkers such as cerebrospinal fluid β-
amyloid [39, 40], plasma β-amyloid [41], hippocampal atro-
phy [41], and amyloid retention in positron emission tom-
ography [42] are associated with SCD. Although the
prevalence of AD pathology in SCD may differ between
memory centers due to their varied study designs [43], SCD
might be an early symptom in the preclinical stage of AD.
Previous studies have reported inconsistent results regard-
ing the association between SCD and non-AD dementia,
such as vascular dementia, Lewy body dementia, and fron-
totemporal lobar degeneration [8, 10]. Although the typical
symptoms of dementia differ according to the case, mem-
ory dysfunction could represent an early symptom in all
forms of dementia [44]. Importantly, memory dysfunction
can have diverse manifestations including difficulties with
episodic and semantic memory and encoding, retrieval, and
recognition types of memory. Our results suggest that SCD
can broadly be used as a risk indicator for a myriad of cog-
nitive disorders such as AD and non-AD.
The major strength of our study is that we have used
the largest nationwide representative cohort data to date
relating SCD to subsequent dementia. We analyzed 579,
710 eligible subjects, extracted from over 50 million en-
tries in the NHIS database. Clinical cohorts in SCD re-
search have relatively small to modest numbers of
selective participants, ranging from 42 to 4500 [10, 34].
In addition, studies that have assessed the risks associ-
ated with subjective memory complaints have used di-
verse and inconsistent characteristics, including the
number of participants (17 to 2901), the age of partici-
pants (18 to 87), the follow-up periods (1 to 15 years),
the operational criteria for defining SCD, and the
methods of assessing dementia [6, 12, 34]. Consequently,
when these studies are combined for meta-analysis, the
significant heterogeneity between studies may add sig-
nificant noise towards estimating the association be-
tween SCD and dementia. As an additional strength, our
results are based on the mandatory national healthcare
screening service, which is more reflective of the general
population and might be more robust and generalizable
than studies conducted through memory clinics. In this
study, measuring SCD in a large homogeneous commu-
nity population with comprehensive information enabled
us to investigate SCD and risk for both AD and non-AD
dementia with a wide range of clinical covariates,
extended time frame, consideration of depressive dis-
order and subclinical symptoms, and comparison with
peers of the same age without SCD.
This study also has several limitations. Firstly, the
main weakness is the lack of objective cognition test re-
sults. Normal performance on standardized cognitive
tests is one of the research criteria for SCD [14]. To re-
duce bias related to this limitation, we excluded subjects
with pre-existing cognitive decline from the analysis,
namely subjects with impaired ADLs, a documented his-
tory of dementia, MCI, or a prescription for dementia
medication. Secondly, although we comprehensively ad-
justed for various confounds, we did not consider the
years of education, occupational attainment, family his-
tory, imaging biomarkers, or other potentially relevant
confounds. However, we adjusted for covariates such as
comprehensive disease diagnosis, income level, and
healthcare visit frequency that can only be obtained
from the national data. Thirdly, the operational defin-
ition of AD may be susceptible to misdiagnosis or un-
derdiagnosis, although the incidence rate of AD in our
study population was similar to the rates reported in epi-
demiological studies conducted in South Korea [45].
Fourthly, the age of 66 years of this cohort is relatively
young, and thus, the findings may not represent the en-
tire elderly group. Finally, because the study population
included individuals from only a single country, our
findings may not be generalizable to people of other
backgrounds.
Conclusion
Our study, in a population-based cohort, is the largest to
date and demonstrates the importance of SCD as an early,
independent risk factor for dementia. These findings thus
provide strong evidence for the role of SCD in characteriz-
ing the initial high-risk stage of dementia. As a growing
public health issue, SCD should be further investigated as a
risk factor for dementia. Giving additional attention to SCD
as a risk factor for dementia could facilitate more focused
surveillance from the public and healthcare professionals.
However, it may not be appropriate for the public to view
SCD as a disease state that should be actively treated. In-
stead, an approach focused on prevention for people with
SCD, including lifestyle modifications or providing educa-
tion on dementia, could be promising. Future studies
should further explore the clinical and neurobiological na-
ture of SCD as an early sign of dementia.
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